drugset / Trial / NCT04468347
Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
A Phase 1 study designed to evaluate imaging characteristics of flortaucipir in the preclinical, prodromal and dementia phases of Alzheimer's disease.
Timeline
- Start
- 2014-10
- Primary completion
- 2018-02
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Flortaucipir F18 | Diagnostic / imaging agent | 240 mbq | Intravenous |